Mark J. Ratain to Cell Line, Tumor
This is a "connection" page, showing publications Mark J. Ratain has written about Cell Line, Tumor.
Connection Strength
0.338
-
Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 2018 Oct; 48(10):973-983.
Score: 0.103
-
Genome-wide identification of genetic determinants for the cytotoxicity of perifosine. Hum Genomics. 2008 Sep; 3(1):53-70.
Score: 0.054
-
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6788-95.
Score: 0.052
-
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 2005 Jan 01; 65(1):46-53.
Score: 0.042
-
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
Score: 0.027
-
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9.
Score: 0.018
-
Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. Pharmacogenomics J. 2013 Oct; 13(5):396-402.
Score: 0.018
-
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J. 2009 Feb; 9(1):49-60.
Score: 0.014
-
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 2004 Jun 15; 64(12):4353-6.
Score: 0.010